![]() This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. To learn more, visit or follow us on LinkedIn. Silverback Therapeutics is located in Seattle, Washington. Initially, Silverback is creating a new class of targeted immuno-oncology agents that direct a TLR8 agonist myeloid cell activator to the tumor microenvironment in solid tumors to promote cancer cell killing. Silverback’s platform enables the strategic pairing of proprietary payloads that modulate key disease modifying pathways with monoclonal antibodies directed at specific disease sites. is a clinical-stage biopharmaceutical company focused on leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered and tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Virtual Poster Session Date and Time: The poster will be made available on the AACR website and Silverback website on Apat 8:30 a.m. Session Title: Therapeutic Antibodies, Including Engineered Antibodies ![]() Title: SBT6290, a Systemically Administered Nectin4-Directed TLR8 ImmunoTAC ® Product Candidate, is Designed for Tumor-localized Activation of Myeloid Cells Details of the poster presentation are as follows: The abstract is now available on the AACR Annual Meeting website. Nectin4 is a cell surface adhesion molecule that is overexpressed in multiple solid tumor types including urothelial, triple negative breast, squamous cell head and neck, and non-small cell lung cancers, with limited expression in normal tissues. SBT6290 comprises a selective TLR8 agonist conjugated to a Nectin4-specific monoclonal antibody. We will continue to evaluate SBT6290 in GLP toxicology studies and anticipate submitting an IND for this program in the fourth quarter of 2021.” “These preclinical data show that SBT6290 activates human myeloid cells in a Nectin4-dependent manner and that a SBT6290 mouse surrogate confers single agent anti-tumor activity in preclinical studies. We are building on learnings from SBT6050, leveraging the same TLR8 linker-payload, which is highly transferrable across different targeting antibodies,” said Valerie Odegard, Ph.D., president & chief scientific officer of Silverback Therapeutics. “SBT6290 showcases the versatility of our ImmunoTAC platform and along with our lead program SBT6050, exemplifies our goal to target difficult-to-treat solid tumors subset by subset. The data highlight the ability of SBT6290, a systemically administered Nectin4-directed TLR8 ImmunoTAC product candidate, to selectively activate myeloid cells in the tumor microenvironment, a promising approach to overcome resistance mechanisms associated with most current immunotherapies. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue-targeted therapeutics for the treatment of cancer, chronic viral infections and other serious diseases, will present preclinical data on its second product candidate, SBT6290, at the American Association of Cancer Research (AACR) 2021 Annual Conference, taking place virtually April 10-15. Insider trading is most common in December, with the busiest year in 2020.SEATTLE-( BUSINESS WIRE)-Silverback Therapeutics, Inc. ![]() In the last year, insiders at Silverback Therapeutics, Inc have bought an estimated value of $0 worth of shares. Jonathan Root who bought 2,364 units worth Silverback Therapeutics, Inc's most recent insider trade came on Maby Source: What are Silverback Therapeutics, Inc's Past Insider Trades? Other earnings, plans or compensations of $32,226, and The vast majority of their compensation came in the form of Jonathan Piazza received compensation valued at about $6,209,273 in 2020 after becoming Chief Financial Officer. What was Jonathan Piazza's Salary in 2020?Īs Chief Financial Officer of Silverback Therapeutics, Inc, Jonathan Piazza has a total base salary of $62,664. The service also includes several custom screens such as the Double Dipper that includes a list of companies that are buying back their shares while their insiders are independently buying stock on the open market for their own portfolios. The service includes the popular Insider Weekends articles that highlight the top 5 insider purchases and sales each week as well as detailed analysis of one company each week. Our partner InsideArbitrage provides a full suite of tools and analysis that allows you to find opportunities from the hundreds of insiders transactions filed by company insiders each week.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |